We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Biodegradable Implants Result in Fewer Surgeries

By HospiMedica International staff writers
Posted on 18 Nov 2014
Load bearing, biodegradable implants made from iron-tricalcium phosphate (FE-TCP) degrade completely in the body. More...


Researchers at the Fraunhofer Institute for Manufacturing Technology and Advanced Materials (IFAM; Bremen, Germany) and other Fraunhofer Institutes participating in the DegraLast project joined forces to design degradable bone implants for use in trauma surgery and orthopedics. A principal requirement for the suitable material included a degree of degradation matched to bone growth, so that the resorption of the implant meshed with bone formation. The implants also had to be mechanically stable enough during the entire healing process, and could not have any allergenic effects or cause inflammation.

The researchers decided that a metal-ceramic composite would be a suitable candidate, but found that a key component in the design was to determine the right amount of ceramic as a function of the powder amount, since if the proportion is too high, the material would be brittle and accelerate the degradation of the implant. The final powder composition had a 60% iron alloy component and a 40% beta-tricalcium phosphate (TCP) ceramic component. Finally, they fabricated a biodegradable shoulder suture anchor using a powder injection molding technique.

While shaping processes such as powder injection molding are especially suited in large quantities as fixation elements for standard implants, additive manufacturing methods are often used to produce individual, custom-made implants—such as for bone replacement in the skull area—or implants with defined pore structure. The researchers are thus also testing implants made of magnesium alloys through the use of selective laser melting (SLM). The researchers presented the demonstration anchor at the COMPAMED trade fair, held during November 2014 in Düsseldorf (Germany).

“Iron alloys corrode slowly and ensure high mechanical strength, while ceramic decomposes quickly, stimulates bone growth and aids the ingrowth of the implant,” explained Philipp Imgrund, PhD, manager of the Medical Technology and Life Sciences business field at IFAM. “The degradation rate of the anchor of 240 micrometers per year means that the shoulder anchor would be absorbed by the body completely within one to two years.”

Related Links:

Fraunhofer Institute for Manufacturing Technology and Advanced Materials



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.